Original Article

Korean J Hematol 2006; 41(3):

Published online September 30, 2006

https://doi.org/10.5045/kjh.2006.41.3.179

© The Korean Society of Hematology

siRNA를 이용한 종양세포와 줄기세포에서 텔로머라제 억제

김석진, 송준석, 송창희, 유지현, 유영두, 김준석, 김병수

고려대학 대학원 줄기세포 연구소
고려대학교 내과학

Manipulation of Human Telomerase Activity in Cancer and Stem Cells: Application of siRNA-induced Inhibition of Human Telomerase RNA (hTR)

Seok Jin Kim, Joon Seok Song, Chang Hee Song, Ji Hyun Yoo, Young Do Yoo, Jun Suk Kim, Byung Soo Kim

Department of Internal Medicine, Korea University Medical Center, Institute of Korea University Stem Cell Research,
Department of Medicine, Korea University Graduate School, Seoul, Korea

Abstract

Background:
We have determined the effects of human telomerase RNA inhibiton using siRNA in tumor cells and human embryonic and mesenchymal stem cells.
Methods:
We selected the sequences against the predicted loop; these sequneces were comprised of nucleotides from 76 to 94 residues and from 143 to 163 residues as the target sequences, and we cloned these sequences into pU6sh75 and pU6sh143 cells. Three different kinds of cell lines were used: HeLa, SNUhES3, and human mesenchymal stem cells. The degree of inhibition of telomerase activity was assessed by TRAP assay and RT-PCR.
Results:
The telomerase activity of the HeLa and SNUhES3 cells were 135.3±14.5 and 109.0±18.2; these cells showed higher activity than human mesenchymal stem cells and Wi38 cells (46.3±5.0 and 26.0±12.0), which were control cells. When each of the types of cells was treated with siRNA-hTR, the transfection efficiency of pU6sh75 for the HeLa, SNUhES3, and human mesenchymal stem cells was 91.0±8.4%, 83.3±16.0% and 81.9±12.3%, respectively. In the case of pU6sh143, its transfection efficiency was similar to pU6sh75; the HeLa, SNUhES3 and human mesenchymal stem cells tranfection efficiency was 90.1±9.0%, 79.9±18.2% and 79.4±15.1%, respectively. After two days of transfection, the level of telomerase activity in the pU6sh75 transfected cells decreased to 64.3±10.1% and 56.0±11.0% in the HeLa and SNUhES3 cells, respectively. When the cells were transfected with pU6sh143, the telomerase activity also decreased in the HeLa and SNUhES3 cells (71.3±9.1% and 61.6±8.3%, respectively). However, the difference of telomerase activity was not significant in the human mesenchymal stem cells: 43.0±7.2% with pU6sh75 and 46.0±9.0% with pU6sh143.
Conclusion:
Telomerase RNA inhibiton with siRNA may be a feasible way to inhibit the telomerase activity of human tumor and embryonic stem cells.

Keywords Telomerase, Tumor, Stem cell, siRNA

Article

Original Article

Korean J Hematol 2006; 41(3): 179-185

Published online September 30, 2006 https://doi.org/10.5045/kjh.2006.41.3.179

Copyright © The Korean Society of Hematology.

siRNA를 이용한 종양세포와 줄기세포에서 텔로머라제 억제

김석진, 송준석, 송창희, 유지현, 유영두, 김준석, 김병수

고려대학 대학원 줄기세포 연구소
고려대학교 내과학

Manipulation of Human Telomerase Activity in Cancer and Stem Cells: Application of siRNA-induced Inhibition of Human Telomerase RNA (hTR)

Seok Jin Kim, Joon Seok Song, Chang Hee Song, Ji Hyun Yoo, Young Do Yoo, Jun Suk Kim, Byung Soo Kim

Department of Internal Medicine, Korea University Medical Center, Institute of Korea University Stem Cell Research,
Department of Medicine, Korea University Graduate School, Seoul, Korea

Abstract

Background:
We have determined the effects of human telomerase RNA inhibiton using siRNA in tumor cells and human embryonic and mesenchymal stem cells.
Methods:
We selected the sequences against the predicted loop; these sequneces were comprised of nucleotides from 76 to 94 residues and from 143 to 163 residues as the target sequences, and we cloned these sequences into pU6sh75 and pU6sh143 cells. Three different kinds of cell lines were used: HeLa, SNUhES3, and human mesenchymal stem cells. The degree of inhibition of telomerase activity was assessed by TRAP assay and RT-PCR.
Results:
The telomerase activity of the HeLa and SNUhES3 cells were 135.3±14.5 and 109.0±18.2; these cells showed higher activity than human mesenchymal stem cells and Wi38 cells (46.3±5.0 and 26.0±12.0), which were control cells. When each of the types of cells was treated with siRNA-hTR, the transfection efficiency of pU6sh75 for the HeLa, SNUhES3, and human mesenchymal stem cells was 91.0±8.4%, 83.3±16.0% and 81.9±12.3%, respectively. In the case of pU6sh143, its transfection efficiency was similar to pU6sh75; the HeLa, SNUhES3 and human mesenchymal stem cells tranfection efficiency was 90.1±9.0%, 79.9±18.2% and 79.4±15.1%, respectively. After two days of transfection, the level of telomerase activity in the pU6sh75 transfected cells decreased to 64.3±10.1% and 56.0±11.0% in the HeLa and SNUhES3 cells, respectively. When the cells were transfected with pU6sh143, the telomerase activity also decreased in the HeLa and SNUhES3 cells (71.3±9.1% and 61.6±8.3%, respectively). However, the difference of telomerase activity was not significant in the human mesenchymal stem cells: 43.0±7.2% with pU6sh75 and 46.0±9.0% with pU6sh143.
Conclusion:
Telomerase RNA inhibiton with siRNA may be a feasible way to inhibit the telomerase activity of human tumor and embryonic stem cells.

Keywords: Telomerase, Tumor, Stem cell, siRNA

Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download